Applications are invited from early-stage healthtech ventures with solutions to problems faced by healthcare systems globally. Several will be chosen for investment. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome.
MedCity has partnered with Spex Capital to source, evaluate and fund early-stage healthtech ventures and accelerate their route to commercialisation. This exclusive partnership will support several calls for innovative companies seeking investment over the next two years.
The call is targeted at innovative health tech companies seeking Seed or Series A investment. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million but smaller tickets will be welcome. Successful applicants will also benefit from access to advisory teams with deep sector experience.
Leading from the MedCity side to source and evaluate viable candidates are COO Nicki Bromwich and Programme Lead Sakura Holloway. Nicki Bromwich has 30 years’ experience as a clinician in the NHS and served as Head of Commercial Development at Oxford AHSN before joining MedCity. Sakura Holloway is an IP and commercial strategist in the biotech sector with a technical background in molecular biology.
The call closes at midnight on 27th October 2021. The call is not restricted to UK companies; non-UK companies are welcome to apply. Find out more HERE.